Positive correlation of plasma PCSK9 levels with HbA1c in patients with type 2 diabetes

Diabetes/Metabolism Research and Reviews

Volumn 32, Issue 2, 2016, Pages 193-199

  Yang, Sheng Hua ^a   Li, Sha ^a   Zhang, Yan ^a   Xu, Rui Xia ^a   Guo, Yuan Lin ^a   Zhu, Cheng Gang ^a   Wu, Na Qiong ^a   Cui, Chuan Jue ^a   Sun, Jing ^a   Li, Jian Jun ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Diabetes mellitus; Glycated haemoglobin; HbA1c; PCSK9; Proprotein convertase subtilisin kexin type 9

Indexed keywords

HEMOGLOBIN A1C; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9; SERINE PROTEINASE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; CORONARY ANGIOGRAPHY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS, TYPE 2; FOLLOW UP; MIDDLE AGED; PROGNOSIS;

BIOMARKERS; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROPROTEIN CONVERTASE 9; PROPROTEIN CONVERTASES; RISK FACTORS; SERINE ENDOPEPTIDASES;

EID: 84958163173     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2712     Document Type: Article

References (38)

1. Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 2003; 100(3): 928-933.
2. Alborn WE, Cao G, Careskey HE, et al. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem 2007; 53(10): 1814-1819.
3. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009; 50(Suppl): S172-S177.
4. Cunningham D, Danley DE, Geoghegan KF, et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 2007; 14(5): 413-419.
5. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34(2): 154-156.
6. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354(12): 1264-1272.
7. Niesen M, Bedi M, Lopez D. Diabetes alters LDL receptor and PCSK9 expression in rat liver. Arch Biochem Biophys 2008; 470(2): 111-115.
8. Mbikay M, Sirois F, Mayne J, et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett 2010; 584(4): 701-706.
9. Dong B, Singh AB, Azhar S, Seidah NG, Liu J. High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levels. Atherosclerosis 2015; 239(2): 364-374.
10. Baass A, Dubuc G, Tremblay M, et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 2009; 55(9): 1637-1645.
11. Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009; 94(7): 2537-2543.
12. Cui Q, Ju X, Yang T, et al. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis 2010; 213(2): 632-636.
13. Costet P, Cariou B, Lambert G, et al. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem 2006; 281(10): 6211-6218.
14. Persson L, Galman C, Angelin B, Rudling M. Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors. Endocrinology 2009; 150(3): 1140-1146.
15. Kappelle PJ, Lambert G, Dullaart RP. Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24 h insulin infusion in healthy subjects and type 2 diabetic patients. Atherosclerosis 2011; 214(2): 432-435.
16. Awan Z, Dubuc G, Faraj M, et al. The effect of insulin on circulating PCSK9 in postmenopausal obese women. Clin Biochem 2014; 47(12): 1033-1039.
17. Langhi C, Le May C, Gmyr V, et al. PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion. Biochem Biophys Res Commun 2009; 390(4): 1288-1293.
18. Higgins T. HbA(1c)-an analyte of increasing importance. Clin Biochem 2012; 45(13-14): 1038-1045.
19. Lenters-Westra E, Schindhelm RK, Bilo HJ, Slingerland RJ. Haemoglobin A1c: historical overview and current concepts. Diabetes Res Clin Pract 2013; 99(2): 75-84.
20. Chen Y. Diagnosis of diabetes. N Engl J Med 2013; 368(2): 192-193.
21. Onal ZE, Atasayan V, Gurbuz T, Hepkaya E, Nuhoglu C. Association of glycosylated hemoglobin (HbA1c) levels with Iinsulin resistance in obese children. Afr Health Sci 2014; 14(3): 533-538.
22. Ahmad Khan H. Clinical significance of HbA1c as a marker of circulating lipids in male and female type 2 diabetic patients. Acta Diabetol 2007; 44(4): 193-200.
23. Prabhavathi K, Kunikullaya UK, Goturu J. Glycosylated haemoglobin (HbA1c) - a marker of circulating lipids in type 2 diabetic patients. J Clin Diagn Res 2014; 8(2): 20-23.
24. Cariou B, Le Bras M, Langhi C, et al. Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients. Atherosclerosis 2010; 211(2): 700-702.
25. Costet P, Hoffmann MM, Cariou B, Guyomarc'h Delasalle B, Konrad T, Winkler K. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis 2010; 212(1): 246-251.
26. Li S, Guo YL, Xu RX, et al. Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis. Int J Cardiol 2014; 174(3): 863-864.
27. Zhang Y, Zhu CG, Xu RX, et al. Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease. J Clin Lipidol 2014; 8(5): 494-500.
28. Zhang Y, Xu RX, Li S, et al. Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease. Nutr Metab Cardiovasc Dis 2015; 25(4): 426-433.
29. Brouwers MC, Troutt JS, van Greevenbroek MM, et al. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study. Atherosclerosis 2011; 217(1): 263-267.
30. Lambert G, Ancellin N, Charlton F, et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem 2008; 54(6): 1038-1045.
31. Verges B, Duvillard L, Brindisi MC, et al. Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes. Atherosclerosis 2011; 219(1): 342-348.
32. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ 2013; 346: f2610.
33. Raal FJ, Stein EA, Dufour R, et al. \PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2):a randomised, double-blind, placebo-controlled trial. Lancet 2015; 385(9965): 331-340.
34. Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014; 63(23): 2541-2548.
35. Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012; 308(23): 2497-2506.
36. Besseling J, Kastelein JJ, Defesche JC, Hutten BA, Hovingh GK. Association between familial hypercholesterolemia and prevalence of type 2 diabetes 3mellitus. JAMA 2015; 313(10): 1029-1036.
37. Preiss D, Sattar N. Does the LDL receptor play a role in the risk of developing type 2 diabetes? JAMA 2015; 313(10): 1016-1017.
38. Hoogeveen RC, Gaubatz JW, Sun W, et al. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol 2014; 34(5): 1069-1077.